DisclosureWe earn commission on partner links; ranking is set by our published methodology — not advertisers.
Menopause/perimenopause-related weight gain and metabolic shift. GLP‑1 use here is off-label.
Each score is our overall rating from the clinical rubric (effectiveness, safety, evidence, value). The left rule is color-keyed to the molecule.
Molecule key: Semaglutide Tirzepatide Oral Other GLP-1
FDA-approved tirzepatide for weight loss
FDA-approved semaglutide for chronic weight management
Semaglutide approved for type 2 diabetes
A short read of who wins for which kind of patient.
Recommendation labels are computed from each product’s editorial badges + scoring rubric. See methodology for the full rubric — page /best-glp1-for/menopause.
Subgroup analyses of STEP and SURMOUNT trials show postmenopausal women lose similar percentages of body weight as premenopausal women on semaglutide and tirzepatide. Bone density preservation is a focus area; current data show no significant DEXA changes at 68 weeks on Wegovy.
Standard weight-loss PA pathways apply. BMI ≥ 30, or BMI ≥ 27 with comorbidity, unlocks Wegovy or Zepbound regardless of menopause status. HRT and GLP-1 use are not contraindicated together.
Same as weight-loss PAs. Menopause is not a separate insurance pathway.
Resistance training is critical for postmenopausal women on GLP-1s to preserve lean mass and bone density. Calcium 1200 mg and vitamin D 2000 IU recommended baseline.
For women in perimenopause or early menopause with stubborn weight gain, GLP-1s work as well as in any other adult population. Prioritize resistance training and protein intake (1.4 g/kg) more aggressively than the average user.
For women in perimenopause or early menopause with stubborn weight gain, GLP-1s work as well as in any other adult population. Prioritize resistance training and protein intake (1.4 g/kg) more aggressively than the average user.